Výsledky vyhledávání

5PSQ-074 Fampridine related atrial fibrillation: two case reports

Autor: I Alferez Garcia, E Tejedor Tejada, I Andrade Andrade, B Tauste Hernández

Publikováno v: Section 5: Patient Safety and Quality assurance.

Background and importance Fampridine (4-aminopyridine) is a drug whose indication is to improve gait in adult patients with multiple sclerosis with walking disability (EDSS 4–7). It is important to describe adverse effects that occur in certain pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e280828af286cc1e4b879f67cc4764e1
https://doi.org/10.1136/ejhpharm-2020-eahpconf.391

Zobrazit plný text záznamu

4CPS-135 Effectiveness and cost of eculizumab on patients with atypical (shua), urenic and haemolitic syndrome, with enlargement of the frequency of administration

Autor: S Cañizares Paz, P Nieto Guindo, FSierra García, E Molina Cuadrado, I Alferez, S Cifuentes

Publikováno v: Eur J Hosp Pharm

Background Atypical haemolytic uraemic syndrome (aHUS) is a thrombotic microangiopathy that primarily affects the kidney. Purpose To compare the effectiveness and cost of eculizumab (monoclonal antibody indicated for the treatment of aHUS) on a patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec6fdffa839bcb6baf88b42385450f95
https://europepmc.org/articles/PMC7535341/

Zobrazit plný text záznamu

DI-007 Effectiveness and security of sustained release fampridine in multiple sclerosis in the short term

Autor: E Molina, S Cañizares, S Cifuentes, JM Ruiz, I Alferez, F Sierra

Publikováno v: European Journal of Hospital Pharmacy. 23:A121.1-A121

Background Mobility impairment is a common disability in multiple sclerosis (MS) and negatively impacts patients’ lives. Clinical studies suggest that fampridine improves motor function in people with MS. Purpose To assess the effectiveness and sec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::17ad532c76dc613663d7a08a634de1e6
https://doi.org/10.1136/ejhpharm-2016-000875.274

Zobrazit plný text záznamu

DI-017 Mefloquine in progressive multifocal leukoencephalopathy

Autor: I Alferez Garcia, E Molina Cuadrado, P Nieto Guindo, FD Fernández-Ginés

Publikováno v: European Journal of Hospital Pharmacy. 23:A125.1-A125

Background Natalizumab increases the risk of progressive multifocal leukoencephalopathy (PML), a potentially lethal brain disorder caused by JC polyomavirus (JCV). The antimalarial mefloquine has shown activity against JCV in vitro , but little evide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be94b661d40c12f298367d51418681e6
https://doi.org/10.1136/ejhpharm-2016-000875.284

Zobrazit plný text záznamu

PKP-004 Assessment of compliance of pharmacokinetic monitoring request criteria in vancomycin and aminoglycoside prescriptions

Autor: FD Fernández-Ginés, P Nieto Guindo, I Alferez Garcia, H Mateo Carrasco

Publikováno v: European Journal of Hospital Pharmacy. 23:A179.2-A180

Background Therapeutic drug monitoring is an important means of optimising drug utilisation and doses for the purpose of improving clinical effectiveness. Purpose To assess compliance of vancomycin and aminoglycosides pharmacokinetic monitoring reque

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4eec602fd42eae79a63065f8411da5c
https://doi.org/10.1136/ejhpharm-2016-000875.407

Zobrazit plný text záznamu

CP-008 Deoxynucleotides dtmp and dcmp in the treatment of mitochondrial myopathy by mutations on the TK2 gene

Autor: S Francisco, E Molina, I Alferez, S Cifuentes

Publikováno v: European Journal of Hospital Pharmacy. 23:A4.1-A4

Background Mitochondrial DNA (mtDNA) depletion syndromes (MDS) attribute secondary heterogeneous diseases to defects in the mitochondrial respiratory chain. MDS are due to primary defects in nDNA genes that cause secondary defects in mtDNA. One of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f3a8241b89af81cc5258292e330d4ff0
https://doi.org/10.1136/ejhpharm-2016-000875.8

Zobrazit plný text záznamu

PP-042 Masterly formula effectiveness of diazoxide suspension with sorbitol in a neonatal patient

Autor: P Nieto, I Alferez, D Fernandez, S Cañizares, J Cotrina Luque, E Cuadrado

Publikováno v: European Journal of Hospital Pharmacy. 23:A212.2-A213

Background Congenital hyperinsulinism (HIC) constitutes the more frequent cause of recidivate hypoglycaemia in neonates and lactates. Dose administration of 15 mg/kg/day is the cornerstone of HIC medical treatment. Purpose To evaluate tolerance, effe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5081d9da747089236e3a0da5321d9e1b
https://doi.org/10.1136/ejhpharm-2016-000875.481

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání